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Background. Candida haemulonii, a yeast species that often exhibits antifungal resistance, rarely causes human
infection. During 2004–2006, unusual yeast isolates with phenotypic similarity to C. haemulonii were recovered
from 23 patients (8 patients with fungemia and 15 patients with chronic otitis media) in 5 hospitals in Korea.
Methods. Isolates were characterized using D1/D2 domain and ITS gene sequencing, and the susceptibility of
the isolates to 6 antifungal agents was tested in vitro.
Results. Gene sequencing of the blood isolates confirmed C. haemulonii group I (in 1 patient) and Candida
pseudohaemulonii (in 7 patients), whereas all isolates recovered from the ear were a novel species of which C.
haemulonii is its closest relative. The minimum inhibitory concentration (MIC) ranges of amphotericin B, flu-
conazole, itraconazole, and voriconazole for all isolates were 0.5–32 mg/mL (MIC50, 1 mg/mL), 2–128 mg/mL (MIC50,
4 mg/mL), 0.125–4 mg/mL (MIC50, 0.25 mg/mL), and 0.03–2 mg/mL (MIC50, 0.06 mg/mL), respectively. All isolates
were susceptible to caspofungin (MIC, 0.125–0.25 mg/mL) and micafungin (MIC, 0.03–0.06 mg/mL). All cases of
fungemia occurred in patients with severe underlying diseases who had central venous catheters. Three patients
developed breakthrough fungemia while receiving antifungal therapy, and amphotericin B therapeutic failure,
which was associated with a high MIC of amphotericin B (32 mg/mL), was observed in 2 patients.
Conclusions. Candida species that are closely related to C. haemulonii are emerging sources of infection in
Korea. These species show variable patterns of susceptibility to amphotericin B and azole antifungal agents.
Candida haemulonii is an infrequent cause of human
infection [1–4]. Recently, Sugita et al. [5] isolated a
strain that did not belong to—but that was phyloge-
netically close to—C. haemulonii from the blood of a
patient; this strain was denoted Candida pseudohae-
mulonii sp. nov. In these previous studies, clinical iso-
lates of C. haemulonii and C. pseudohaemulonii were
resistant to both amphotericin B and fluconazole [3–
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5]. Because drug resistance is a major problem in the
treatment of yeast infection, identification of clinical
isolates of these species is very important. However,
conventional yeast identification systems have failed to
identify C. haemulonii or C. pseudohaemulonii isolates
[3–5].
During a multiple-center surveillance study con-
ducted in Korea, we identified unusual yeast isolates
with phenotypic similarities to C. haemulonii in 5 of
the 11 participating hospitals. During the period 2004–
2006, a total of 27 isolates were recovered from 23
patients (8 had fungemia, and 15 had chronic otitis
media). In this study, we characterized these isolates by
sequencing the internal transcribed spacer region and
the D1/D2 domain of the large-subunit rRNA gene,
and we determined the in vitro susceptibility of the
isolates to 6 antifungal agents. For the first time, we
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describe the antifungal resistance and relevant clinical features
of Candida species closely related to C. haemulonii.
METHODS
Microorganisms. This study analyzed 27 isolates (12 isolates
recovered from blood samples from 8 patients and 15 isolates
recovered from middle ear specimens from 15 patients) that
were collected during the period May 2004–December 2006 at
5 university hospitals in Korea. All isolates were identified as
C. haemulonii using the Vitek 2 YST system (bioMe´rieux) and
were then reidentified using conventional identification meth-
ods, including API 20C (bioMe´rieux). In addition, clinical in-
formation was collected retrospectively and included patient
demographic characteristics, clinical diagnosis, presence of a
central venous catheter, receipt of antifungal therapy, and out-
come of fungemia [6, 7]. Therapeutic failure was defined either
as the persistence of Candida in the bloodstream despite receipt
of 3 days of antifungal therapy or as the development of break-
through candidemia while receiving antifungal agents for 3 days
[8, 9].
Sequencing the internal transcribed spacer region and D1/
D2 domain. The first isolates from each of the 23 patients
(isolates 1–23) were analyzed. The internal transcribed spacer
region (including the 5.8S rRNA gene) and D1/D2 domain of
the large-subunit rRNA gene were amplified using the primer
pairs pITS-F and pITS-R [10] and NL1 and NL4 [11], respec-
tively. Sequence similarity searches were performed using
BLAST at the NCBI database (http://www.ncbi.nlm.nih.gov/
blast). The D1/D2 domain sequences of 8 blood and 15 ear
isolates have been deposited in GenBank (accession numbers
EU881946–EU881953 for isolates 1–8 and EU881954–
EU881968 for isolates 9–23, respectively; the internal tran-
scribed spacer–region sequences were given accession numbers
EU881969–EU881976 for isolates 1–8 and EU884176–
EU884190 for isolates 9–23, respectively). Five representative
isolates (isolates 1–3, 9, and 10) were deposited in the Korea
Collection for Type Culture (Daejeon, Korea) as strains KCTC
17806–17810.
Antifungal susceptibility testing. The in vitro susceptibil-
ities of the isolates to amphotericin B were determined using
the Etest (AB Biodisk) according to the manufacturer’s instruc-
tions [12]. Antifungal susceptibilities to fluconazole, itracon-
azole, voriconazole, caspofungin, and micafungin were tested
using the standard methods of the Clinical and Laboratory
Standards Institute [13, 14]. The interpretive susceptibility cri-
teria used for fluconazole and itraconazole were those specified
by the Clinical and Laboratory Standards Institute [13]. For
voriconazole, we used the tentative interpretative breakpoints
recently established for use with Candida species [15].
RESULTS
Species identification. The identification and antifungal sus-
ceptibilities of 27 isolates recovered from 23 patients are shown
in table 1. The D1/D2 domain and internal transcribed spacer
sequences of isolate 1 (from patient 1) demonstrated 99%–
100% identity with those of reference strains of C. haemulonii
group I available in GenBank, and this isolate was confirmed
to be C. haemulonii group I. The blood isolates recovered from
patients 2–8 were identical and were 100% homologous to the
sequence of C. haemulonii DMST 17134, which has recently
been designated C. pseudohaemulonii. All ear isolates (from
patients 9–23) constituted a novel species that is closely related
to C. haemulonii. All isolates recovered from the 23 patients
were identified as C. haemulonii using the Vitek 2 YST yeast
card system. With use of the API 20C system, the blood isolates
recovered from patients 1–8 were identified as Kodamaea
ohmeri, whereas the ear isolates recovered from patients 9–23
were identified as Rhodotorula glutinis.
Antifungal susceptibilities. The MIC of amphotericin B
ranged from 0.5 to 32 mg/mL (MIC50, 1 mg/mL) for all 27
isolates. High-level amphotericin B resistance (MIC, 32 mg/mL)
was observed for blood isolates of C. pseudohaemulonii recov-
ered from 5 patients (patients 2, 3, and 6–8). The MICs of
fluconazole, itraconazole, and voriconazole for all 27 isolates
were 2–128 mg/mL (MIC50, 4 mg/mL), 0.125–4 mg/mL (MIC50,
0.25 mg/mL), and 0.03–2 mg/mL (MIC50, 0.06 mg/mL), respec-
tively. Blood isolates of C. haemulonii from patient 1 and ear
isolates from the 7 other patients were resistant to both flu-
conazole and itraconazole and showed decreased susceptibility
to voriconazole (MIC, 0.5–1 mg/mL). All 27 isolates were sus-
ceptible to caspofungin (MIC, 0.125–0.25 mg/mL) and mica-
fungin (MIC, 0.03–0.06 mg/mL) (table 1).
Clinical characteristics of the patients. The clinical char-
acteristics of all 8 patients with fungemia are summarized in
figure 1. All patients had severe underlying diseases and central
venous catheters. Two patients (patients 1 and 2) had neutro-
penia. Four patients (50%) had previously received antifungal
therapy, and breakthrough fungemia developed in 3 patients
while they were receiving itraconazole (patient 1), fluconazole
(patient 2), or both fluconazole and amphotericin B (patient
7). Of the 3 patients (patients 2, 4, and 5) who received am-
photericin B therapy for fungemia, 2 experienced amphotericin
B therapeutic failure. Patient 4, who had severe immunodefi-
ciency, died despite having received 4 days of amphotericin B
therapy; his isolate had an MIC of amphotericin B of 0.5 mg/
mL. Patient 2, whose isolates were found to have an MIC of
amphotericin B of 32 mg/mL, experienced persistent candide-
mia despite having received 12 days of amphotericin B therapy
and finally died. Patient 5, however, whose isolate demonstrated
an MIC of amphotericin B of 0.5–1 mg/mL, recovered after
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Table 1. Results of identification and antifungal susceptibility testing for 27 isolates recovered from 23 patients.
Patient,
isolate Hospital Source
Identification by
D1/D2 domain and
ITS sequence analysis Vitek 2 YST resulta
API 20C data MIC, mg/mL
Resulta Code no. AMB FLU ITR VOR Casp Mica
1
1 A Blood Candida haemulonii group I C. haemulonii (89) Kodamaea ohmeri (75.3) 6002174 1 64 4 1 0.125 0.06
1a A Blood NT C. haemulonii (89) K. ohmeri (75.3) 6002174 2 64 4 1 0.125 0.06
2: 2 A Blood Candida pseudohaemulonii C. haemulonii (95) K. ohmeri (98.6) 6142136 32 2 0.25 0.03 0.125 0.06
3: 3 B Blood C. pseudohaemulonii C. haemulonii (92) K. ohmeri (99.9) 6142176 32 4 0.125 0.06 0.125 0.03
4: 4 B Blood C. pseudohaemulonii C. haemulonii (93) K. ohmeri (99.9) 6142176 0.5 2 0.125 0.06 0.125 0.03
5
5 B Blood C. pseudohaemulonii C. haemulonii (92) K. ohmeri (99.9) 6142176 0.5 2 0.25 0.06 0.125 0.03
5a B Blood NT C. haemulonii (88) K. ohmeri (99.9) 6142176 0.5 2 0.25 0.06 0.125 0.03
5b B Blood NT C. haemulonii (92) K. ohmeri (99.9) 6142176 1 4 0.25 0.06 0.125 0.03
5c B Blood NT C. haemulonii (92) K. ohmeri (99.9) 6142176 0.75 4 0.25 0.06 0.125 0.03
6: 6 B Blood C. pseudohaemulonii C. haemulonii (92) K. ohmeri (99.9) 6142176 32 4 0.125 0.06 0.125 0.03
7: 7 B Blood C. pseudohaemulonii C. haemulonii (95) K. ohmeri (81.7) 6002136 32 2 0.125 0.06 0.125 0.03
8: 8 B Blood C. pseudohaemulonii C. haemulonii (97) K. ohmeri (99.2) 6106136 32 2 0.125 0.06 0.125 0.03
9: 9 C Ear Candida sp. nov.b C. haemulonii (98) Rhodotorula glutinis (99.9) 6102073 1 128 2 1 0.125 0.03
10: 10 C Ear Candida sp. nov. C. haemulonii (94) R. glutinis (99.9) 2102073 1.5 128 2 0.5 0.25 0.06
11: 11 C Ear Candida sp. nov. C. haemulonii (99) R. glutinis (99.9) 6102073 0.75 8 0.5 0.125 0.125 0.03
12: 12 C Ear Candida sp. nov. C. haemulonii (91) R. glutinis (99.9) 6102073 1.5 128 2 2 0.25 0.03
13: 13 C Ear Candida sp. nov. C. haemulonii (89) R. glutinis (99.9) 6102073 0.5 128 2 1 0.25 0.03
14: 14 C Ear Candida sp. nov. C. haemulonii (95) R. glutinis (99.9) 6102073 0.38 64 1 0.5 0.125 0.03
15: 15 C Ear Candida sp. nov. C. haemulonii (89) R. glutinis (99.9) 6102073 0.38 64 2 1 0.25 0.03
16: 16 C Ear Candida sp. nov. C. haemulonii (99) R. glutinis (99.9) 6102073 0.75 32 1 0.25 0.25 0.03
17: 17 D Ear Candida sp. nov. C. haemulonii (99) R. glutinis (99.5) 2102073 1.5 4 0.125 0.03 0.125 0.03
18: 18 D Ear Candida sp. nov. C. haemulonii (95) R. glutinis (99.9) 6102073 1 4 0.125 0.03 0.125 0.03
19: 19 D Ear Candida sp. nov. C. haemulonii (91) R. glutinis (99.9) 2102173 1 2 0.25 0.03 0.125 0.03
20: 20 D Ear Candida sp. nov. C. haemulonii (99) R. glutinis (99.9) 6102073 1.5 4 0.125 0.03 0.125 0.03
21: 21 E Ear Candida sp. nov. C. haemulonii (99) R. glutinis (99.9) 2102173 1 2 0.125 0.03 0.25 0.03
22: 22 E Ear Candida sp. nov. C. haemulonii (98) R. glutinis (99.9) 6102073 0.75 4 0.125 0.06 0.25 0.03
23: 23 E Ear Candida sp. nov. C. haemulonii (99) R. glutinis (99.9) 6102073 1.5 64 4 2 0.25 0.03
NOTE. Antifungal MICs were determined using Etest (AB Biodisk) for amphotericin B (AMB) and the Clinical and Laboratory Standards Institute broth
microdilution method for the remaining antifungals. Vitek 2 YST and API 20C were manufactured by bioMe´rieux. Casp, caspofungin; FLU, fluconazole; ITR,
itraconazole; ITS, internal transcribed spacer region; Mica, micafungin; NT, not tested; VOR, voriconazole.
a Numbers in parenthesis are the probability of correct identification (as a percentage).
b All of the ear isolates (isolates 9–23) constituted a novel species that is closely related to C. haemulonii.
fluconazole therapy was switched to amphotericin B therapy.
Therapeutic failure was observed in 6 patients (patients 1–5
and 7), and 3 patients (patients 2, 4, and 7) died of uncontrolled
septicemia.
A novel species closely related to C. haemulonii was isolated
from the ears of 15 patients (12 adult and 3 pediatric patients)
who had chronic otitis media. All of these patients had a history
of antibiotic use, and 7 had undergone surgery, including tym-
panoplasty, mastoidectomy, or ventilation tube insertion. Eight
patients had a single positive culture result, and 5 of these
cultures also grew Candida parapsilosis or Staphylococcus aureus.
Persistent positive culture results occurred for 7 patients for
periods lasting from 48 to 353 days. Direct microscopic ex-
amination also revealed the presence of yeasts and neutrophils
in the ear specimens, although no histopathologic evidence of
fungal infection was obtained in any of these patients. Of these
7 patients, 3 received antifungal therapy. The ear symptoms in
1 patient (patient 11) disappeared after 60 days of amphotericin
B therapy (total dose, 3 g), whereas 2 patients (patients 9 and
10) who received fluconazole (for 3 days) or itraconazole (for
7 days) required follow-up as outpatients, because their ear
symptoms did not improve.
DISCUSSION
To date, very little is known regarding the clinical characteristics
and antifungal susceptibility profiles of clinical isolates of Can-
dida species closely related to C. haemulonii. Through the char-
acterization of 23 patient isolates recovered from 5 Korean
hospitals during 2004–2006, we demonstrated the emergence
of C. haemulonii (1 patient), C. pseudohaemulonii (7 patients),
and a novel species closely related to C. haemulonii (15 patients)
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Figure 1. Treatment regimens, MICs for Candida isolates, and outcomes for 8 patients with fungemia due to Candida haemulonii (patient 1) or
Candida pseudohaemulonii (patients 2–8). All patients had central venous catheters in place when the first positive culture results were obtained,
and cultures of the catheter tips removed from 6 patients (patients 1, 3–6, and 8) yielded 115 colonies of the same Candida species. Therapeutic
failure, which was defined either as persistence of Candida species in the bloodstream despite receipt of 3 days of antifungal therapy or as development
of breakthrough candidemia during receipt of a 3-day course of antifungal therapy, was observed in 6 patients (patients 1–5 and 7). Of the 5 patients
(patients 2, 3, 6, 7, and 8) whose isolates demonstrated high MICs of amphotericin B (AMB; 32 mg/mL), 2 patients (patients 2 and 7) received AMB
therapy, and both patients experienced AMB therapeutic failure. F, female; FLU, fluconazole; ITR, itraconazole; M, male, mo, months; yr, years.
in Korea. During the study period, these species accounted for
∼0.5% of 1601 cases of candidemia and 0.1% of 13,869 otitis
media cases in Korean hospitals. These species are noteworthy
for their variable antifungal susceptibility patterns.
In this study, all 23 patient isolates were misidentified by the
API 20C system, but all were identified correctly at the species
level via ITS2 and D1/D2 domain sequence analysis. The Vitek
2 YST system, which was introduced in Korea in 2006, iden-
tified all isolates as C. haemulonii. Therefore, in clinical mi-
crobiology laboratories, biochemical investigations using the
Vitek YST system can be routinely applied to identify pre-
sumptive isolates of C. haemulonii and closely related species,
although molecular diagnostic tools for accurate identification
at the species level should also be employed.
In previous reports, all isolates of C. haemulonii and C. pseu-
dohaemulonii were resistant to both amphotericin B and flucon-
azole [3–5]. However, we found that our isolates, which we re-
covered from 23 patients, demonstrated variable patterns of
susceptibility to amphotericin B (MIC, 0.5–32 mg/mL) and flu-
conazole (MIC, 2–128 mg/mL). The fluconazole-resistant strains
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recovered from 8 patients (35%) appeared to demonstrate azole
cross-resistance (MIC of itraconazole, 1–4 mg/mL; MIC of vor-
iconazole, 0.5–2 mg/mL). Although no antifungal resistance
evolved in serial cultures of specimens obtained from the same
patient, the genotyping results revealed that all ear isolates, for
which the MIC of fluconazole was 2–128 mg/mL, had the same
or similar genotypes (data not shown). These findings combined
suggest that these species are innately less susceptible to flucona-
zole (MIC, 2 mg/mL) than are most other species of Candida
and that they may develop high-level resistance to fluconazole,
similar to Candida glabrata [6].
Both C. haemulonii and C. pseudohaemulonii are reported to
be susceptible to caspofungin and micafungin [4, 5]. In this
study, for all 27 isolates, the MIC ranges for caspofungin and
micafungin were 0.125–0.25 mg/mL and 0.03–0.06 mg/mL, re-
spectively, suggesting that these 2 echinocandins are active
against not only C. haemulonii isolates, but also against isolates
of the 2 Candida species that are closely related to C.
haemulonii.
Fungemia due to C. pseudohaemulonii is extremely rare; to
our knowledge, there has been only 1 documented case [5]. In
this article, we report 7 cases of C. pseudohaemulonii fungemia
and 1 case of C. haemulonii fungemia identified at 2 hospitals
in Korea. The most common underlying condition for the pa-
tients was central venous catheter use. Breakthrough fungemia
developed in 3 patients, and therapeutic failure was observed
in 6 patients. Therapeutic success was not observed when the
patient was administered an antifungal drug to which the isolate
was highly resistant. Of the 5 patients whose isolates had an
MIC of amphotericin B of 32 mg/mL, 2 received amphotericin
B therapy, and both experienced amphotericin B therapeutic
failure: one patient (patient 7) developed breakthrough fun-
gemia during amphotericin B therapy, and the other (patient
2) had persistent candidemia despite having received 12 days
of amphotericin B therapy. This demonstrates that a high MIC
of amphotericin B is associated with therapeutic failure.
It is difficult to judge the clinical significance of Candida
isolates recovered from ear specimens, and confirmation gen-
erally requires histopathologic examination. Although the ear
isolates were repeatedly detected in specimens from 7 patients,
histopathologic proof of fungal infection was not obtained for
any of these patients. Instead, 8 patients had only a single
positive culture result, and some had mixed culture results,
suggesting that this new species is a commensal in the middle
ear. Although the specific reasons for ear involvement of the
new species are not fully understood, we found that isolation
of this species was often accompanied by frequent manipulation
of the ear canal and the use of antibiotics. In addition, geno-
typing results for all 15 isolates from 3 hospitals suggest intra-
and interhospital transmission of a clonal strain in Korea. Ad-
ditional studies are needed to assess the role for this species in
the development or maintenance of chronic otitis media.
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